Screening Methods for Antiparkinsonian Drugs

Introduction and the central problem

• Definition — the systematic in vitro, ex vivo and in vivo evaluation of a candidate for its ability to reverse an experimentally induced parkinsonian phenotype and/or protect nigrostriatal dopaminergic neurones from a degenerative insult.
• The defining obstacle — patients show rigidity, resting tremor and hypokinesia, but rodents and primates per se do not exhibit these signs — there is no spontaneous animal analogue of PD, so every model is an artificially induced surrogate. The logic was historically reverse-translational: drugs that caused parkinsonism in patients (reserpine, phenothiazines) became the laboratory's modelling tools.
• Substrate to reproduce — dopamine deficiency in the basal ganglia from substantia nigra pars compacta degeneration, leaving a relative cholinergic excess — which is why both dopaminergic agonists and muscarinic antagonists work, and why cholinomimetic-challenge models are legitimate.
• Two objectives — separate them at the design stage — symptomatic screening (reserpine, catalepsy, oxotremorine) versus disease-modifying / neuroprotective screening (6-OHDA, MPTP, FeCl₃, rotenone). The second is the unmet need: no single agent is capable of controlling neuronal degeneration; they only provide symptomatic relief.